Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 149, Issue 1, Pages 200-213Publisher
WILEY
DOI: 10.1002/ijc.33539
Keywords
breast cancer; gene expression profiling; oestrogen receptor positive; progesterone receptor negative; SUZ12
Categories
Funding
- Bourgogne-Franche-Comte Regional Council
Ask authors/readers for more resources
The study confirmed that ER-/PR+ breast cancers are an extremely rare but real subtype, morphologically and histologically similar to triple-negative tumors, with more aggressive phenotypes and differing responses to therapies and clinical outcomes. The likely involvement of SUZ12 in their biology offers potential for the development of new therapeutic alternatives.
Determining the status of steroid hormone receptors [oestrogen (ER) and progesterone receptors (PR)] is a crucial part of the breast cancer workup. Thereby, breast cancers can be classified into four subtypes. However, the existence of ER-/PR+ tumours, often reported to be ill-classified due to technical errors, remains controversial. In order to address this controversy, we reviewed the hormone receptor status of 49 breast tumours previously classified as ER-/PR+ by immunohistochemistry, and compared clinical, pathological and molecular characteristics of confirmed ER-/PR+ tumours with those of ER+ and triple-negative tumours. We unequivocally confirmed the ER-/PR+ status in 27 of 49 tumours (0.3% of all breast cancers diagnosed in our institution between 2000 and 2014). We found that ER-/PR+ were morphologically and histologically similar to triple-negative tumours, but very distinct from ER+ tumours, with more aggressive phenotypes and more frequent basal marker expression than the latter. On the molecular level, RNA sequencing revealed different gene expression profiles between the three groups. Of particular interest, several genes controlled by the suppressor of zest 12 (SUZ12) were upregulated in ER-/PR+ tumours. Overall, our results confirm that ER-/PR+ breast cancers are an extremely rare but 'real' tumour subtype that requires careful diagnosis and has distinct features warranting different responsiveness to therapies and different clinical outcomes. Studies on larger cohorts are needed to further characterise these tumours. The likely involvement of SUZ12 in their biology is an interesting finding which may - in a long run - give rise to the development of new therapeutic alternatives.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available